Literature DB >> 23673472

Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Kazuaki Matsumoto1, Yoshio Takesue, Norio Ohmagari, Takahiro Mochizuki, Hiroshige Mikamo, Masafumi Seki, Shunji Takakura, Issei Tokimatsu, Yoshiko Takahashi, Kei Kasahara, Kenji Okada, Masahiro Igarashi, Masahiro Kobayashi, Yukihiro Hamada, Masao Kimura, Yoshifumi Nishi, Yusuke Tanigawara, Toshimi Kimura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23673472     DOI： 10.1007/s10156-013-0599-4

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN： 1341-321X            Impact factor:   2.211


× No keyword cloud information.
  57 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.

Authors:  Katsuhiro Miura; Masaru Nakagawa; Hiromichi Takahashi; Yoshihito Uchino; Hitomi Kodaira; Noriyoshi Iriyama; Masashi Sakagami; Shimon Ohtake; Sumiko Kobayashi; Atsuko Hojo; Daisuke Kurita; Yujin Kobayashi; Machiko Kusuda; Yukio Hirabayashi; Yoshihiro Hatta; Masami Takei
Journal:  Int J Hematol       Date:  2015-12-29       Impact factor: 2.490

3.  Initial dosing regimen of vancomycin to achieve early therapeutic plasma concentration in critically ill patients with MRSA infection based on APACHE II score.

Authors:  Masaharu Imaura; Haruko Yokoyama; Yuji Kohata; Riichiro Kanai; Tomoki Kohyama; Wataru Idemitsu; Yuichi Maki; Takashi Igarashi; Hiroyuki Takahashi; Hiroshi Kanno; Yasuhiko Yamada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-12       Impact factor: 2.441

4.  A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin.

Authors:  Zhi-Kang Ye; Ken Chen; Yao-Long Chen; Suo-di Zhai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05

5.  Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application.

Authors:  Kazutaka Oda; Yumi Hashiguchi; Toshimi Kimura; Yasuhiro Tsuji; Kensuke Shoji; Yoshiko Takahashi; Kazuaki Matsumoto; Hideki Kawamura; Hideyuki Saito; Yoshio Takesue
Journal:  Pharm Res       Date:  2021-03-29       Impact factor: 4.200

6.  Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution.

Authors:  Qiang Li; Fenghua Liang; Ling Sang; Pengpeng Li; Bijun Lv; Lu Tan; Xiaoqing Liu; Wenying Chen
Journal:  Eur J Clin Pharmacol       Date:  2019-11-16       Impact factor: 2.953

7.  Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.

Authors:  Wei-Wei Lin; Wei Wu; Zheng Jiao; Rong-Fang Lin; Chang-Zhen Jiang; Pin-Fang Huang; Yi-Wei Liu; Chang-Lian Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-10-01       Impact factor: 2.953

8.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

9.  Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.

Authors:  Naoto Okada; Masayuki Chuma; Momoyo Azuma; Shingen Nakamura; Hirokazu Miki; Hirofumi Hamano; Mitsuhiro Goda; Kenshi Takechi; Yoshito Zamami; Masahiro Abe; Keisuke Ishizawa
Journal:  Eur J Clin Pharmacol       Date:  2019-09-11       Impact factor: 2.953

10.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.